Hillsborough, CA, United States of America

Warner C Greene

This inventor holds 15 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Lentivirus Research. Top assignees: The J. David Gladstone Institutes, University of California, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone. Active years: 2001-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Warner C Greene. Retrieved from https://idiyas.com/inventor/warner-c-greene

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 60.0


Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 13(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2022)
  • Hillsborough, CA (US) (2001 - 2023)
  • San Francisco, CA (US) (2003 - 2024)

Company Filing History:


Years Active: 2001-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Lentivirus
HIV Treatment
Immunodeficiency Virus
Coagulopathy
GSK-3 Inhibitor
NKG2D Ligands
Virion-Based Assay
NF-KB Modulators
Inflammatory Response
Cell Delivery
Latent HIV Activation
Nucleic Acids
15 patents (USPTO):Explore Patents

Title: Warner C Greene: Innovator in Medical Research

Introduction

Warner C Greene is a prominent inventor based in Hillsborough, CA, known for his significant contributions to medical research. He holds a total of 15 patents, showcasing his innovative approach to addressing critical health issues.

Latest Patents

One of his latest patents is an animal model for SARS-CoV-2-spike induced coagulopathy. This model is designed to identify therapeutic agents that can mitigate the physiological effects of COVID-19 infection, including inflammation, oxidative stress, fibrin deposition, blood-brain barrier breakdown, clotting, and vascular problems. Another notable patent involves compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor. This patent outlines the use of glycogen synthase kinase 3 inhibitors, such as Tideglusib and SB-216763, to reactivate latent immunodeficiency virus.

Career Highlights

Warner C Greene has worked with esteemed institutions, including the J. David Gladstone Institutes and the University of California. His work has significantly advanced the understanding of viral infections and their treatment.

Collaborations

Throughout his career, Greene has collaborated with notable colleagues, including Michael P Sherman and Ulrich Schubert. These partnerships have further enriched his research and innovation efforts.

Conclusion

Warner C Greene's contributions to medical research through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to impact the development of therapeutic solutions for critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…